Patents Assigned to Genentech
  • COMPOSITIONS AND METHODS FOR USING ANTI-IL-34 ANTIBODIES TO TREAT NEUROLOGICAL DISEASES
    Publication number: 20180222974
    Abstract: The invention provides methods for treating neurological diseases and reducing microglia density using anti-IL-34 antibodies.
    Type: Application
    Filed: November 29, 2017
    Publication date: August 9, 2018
    Applicant: Genentech, Inc.
    Inventors: Courtney EASLEY-NEAL, Robby WEIMER, Ali Akbar ZARRIN
  • ANTIBODY FORMULATIONS
    Publication number: 20180221488
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: March 26, 2018
    Publication date: August 9, 2018
    Applicant: Genentech, Inc.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • PYRIDAZINE DERIVATIVES AS RORc MODULATORS
    Publication number: 20180222882
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, A, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: November 1, 2017
    Publication date: August 9, 2018
    Applicant: Genentech, Inc.
    Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward
  • PD-L1 PROMOTER METHYLATION IN CANCER
    Publication number: 20180216196
    Abstract: This invention provides methods for the treatment of cancer in subjects having medium or low methylation level in the PD-L1 promoter region. Also provided are related kits and articles of manufacture.
    Type: Application
    Filed: November 22, 2017
    Publication date: August 2, 2018
    Applicant: Genentech, Inc.
    Inventors: Edward KADEL, Marcin KOWANETZ, Kimberly WALTER
  • High concentration antibody and protein formulations
    Patent number: 10034940
    Abstract: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: July 31, 2018
    Assignees: Genentech, Inc., Novartis AG
    Inventors: Jun Liu, Steven J. Shire
  • Methods and compositions for targeting polyubiquitin
    Patent number: 10035849
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: July 31, 2018
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa Matsumoto
  • Pyrazolo compounds and uses thereof
    Patent number: 10035801
    Abstract: Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 31, 2018
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Victor S. Gehling, Jean-Christophe Harmange, Kwong Wah Lai, Jun Liang, Peter Dragovich, Daniel F. Ortwine, Sharada Labadie, Birong Zhang, James Richard Kiefer
  • Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
    Patent number: 10034860
    Abstract: Described herein are methods of treating locally advanced or metastatic estrogen receptor positive breast cancer.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: July 31, 2018
    Assignee: Genentech, Inc.
    Inventors: Edna Chow Maneval, Boa Tran H. Troung, Isan Chen, Jeffrey H. Hager, Debasish F. Roychowdhury
  • Method of treating retinopathy with an anti-LRP5 antibody
    Patent number: 10035854
    Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: July 31, 2018
    Assignee: GENENTECH, INC.
    Inventors: Yan Wu, Weilan Ye, Jeremy Bryant Burton, Cecilia Chiu
  • COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS
    Publication number: 20180209982
    Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides methods for determining the prognosis and efficacy of STEAP1-ADC therapy in patients with prostate cancer, specifically metastatic castration resistant prostate cancer (mCRPC).
    Type: Application
    Filed: October 20, 2017
    Publication date: July 26, 2018
    Applicants: Genentech, Inc., EPIC SCIENCES INC.
    Inventors: Omar KABBARAH, Iliana SZAFER-GLUSMAN, Dena MARRINUCCI, Florence LEE, Shannon WERNER
  • KLOTHO BETA
    Publication number: 20180208677
    Abstract: The invention concerns uses of anti-KL? agents, and detection of KL? and/or FGF19 and/or FGFR4.
    Type: Application
    Filed: September 11, 2017
    Publication date: July 26, 2018
    Applicant: Genentech, Inc.
    Inventor: Luc Desnoyers
  • Biheteroaryl compounds and uses thereof
    Patent number: 10028954
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: July 24, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Alan G Olivero, Snahel Patel, Michael Siu, Joseph Lyssikatos
  • 3-substituted pyrazoles and uses thereof
    Patent number: 10028942
    Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 24, 2018
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Wen Liu, Snahel Patel, Michael Siu
  • VEGF polymorphisms and anti-angiogenesis therapy
    Patent number: 10031141
    Abstract: Methods for determining whether a patient in at particular risk of hypertension associated with anti-VEGF treatment or has a greater likelihood of benefiting from anti-VEGF therapy by screening a sample isolated from the patient for specific genomic polymorphisms.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: July 24, 2018
    Assignee: Genentech, Inc.
    Inventors: Bryan P. Schneider, Milan Radovich, George W. Sledge
  • Anti-mesothelin antibodies and immunoconjugates
    Patent number: 10022452
    Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 17, 2018
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Suzanna J. Scales, Susan D. Spencer, Yin Zhang
  • Pyrrolidine amide compounds as histone demethylase inhibitors
    Patent number: 10022354
    Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 17, 2018
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS INC.
    Inventors: Kwong Wah Lai, Jun Liang, Birong Zhang, Sharada Labadie, Daniel Ortwine, Peter Dragovich, James Kiefer, Victor S. Gehling, Jean-Christophe Harmange
  • METHODS OF TREATING FGFR3 RELATED CONDITIONS
    Publication number: 20180194844
    Abstract: Provided herein are biomarkers and therapies for the treatment of pathological conditions, such as cancer, and method of using FGFR3 antagonists. In particular, provided is FGFR3 as a biomarker for patient selection and prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Application
    Filed: October 19, 2017
    Publication date: July 12, 2018
    Applicant: Genentech, Inc.
    Inventor: Dorothy French
  • METHODS AND BIOMARKERS FOR PREDICTING EFFICACY AND EVALUATION OF AN OX40 AGONIST TREATMENT
    Publication number: 20180195133
    Abstract: The present disclosure provides methods for predicting responsiveness of a subject having cancer to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Also provided are methods for monitoring pharmacodynamic activity of or responsiveness to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Further provided are methods related thereto for treating or delaying progression of cancer in a subject by administering an effective amount of an OX40 agonist to a subject. Specific biomarkers for all such methods are described herein.
    Type: Application
    Filed: December 8, 2017
    Publication date: July 12, 2018
    Applicant: Genentech, Inc.
    Inventor: Mahrukh HUSENI
  • Antibodies and immunoconjugates
    Patent number: 10017577
    Abstract: The invention provides immunoconjugates and methods of using the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: July 10, 2018
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Peter Dragovich, Thomas Harden Pillow, Shang-Fan Yu
  • Cell culture compositions with antioxidants and methods for polypeptide production
    Patent number: 10017732
    Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 10, 2018
    Assignee: GENENTECH, INC.
    Inventors: Natarajan Vijayasankaran, Steven J. Meier, Sharat Varma, Yi Yang